KARACHI: GlaxoSmithKline Pakistan Limited (GSK Pakistan) reported a strong financial performance for the quarter ended March 31, 2026, posting a notable increase in profitability driven by higher sales and improved operating performance. The company announced that its Board of Directors approved the quarterly financial results at a meeting held on April 27, 2026. No cash dividend, bonus shares, right shares, or any other corporate action were declared for the period.
During the first quarter of 2026, GSK Pakistan’s revenue from contracts with customers increased to Rs. 17.03 billion, compared to Rs. 15.58 billion in the corresponding period last year. The company’s gross profit rose to Rs. 6.38 billion from Rs. 5.33 billion, reflecting healthy top-line growth despite higher selling, marketing, and administrative expenses.
Operating profit improved significantly to Rs. 4.31 billion, up from Rs. 3.63 billion a year earlier. Although other income declined and operating expenses increased, the company maintained strong profitability through improved business performance and controlled financial costs.
Profit before tax reached Rs. 4.29 billion, compared with Rs. 3.52 billion in the same quarter of 2025. After accounting for taxation of Rs. 1.68 billion, GSK Pakistan posted a net profit of Rs. 2.61 billion, representing a 22.8% year-on-year increase from Rs. 2.13 billion reported in the corresponding period last year. Earnings per share (EPS) also improved to Rs. 8.20, up from Rs. 6.68.
The company’s financial position remained robust, with total assets increasing to Rs. 53.99 billion as of March 31, 2026, from Rs. 50.68 billion at the end of December 2025. Shareholders’ equity also strengthened to Rs. 36.29 billion, reflecting the impact of higher retained earnings during the quarter. The cash flow statement showed a substantial improvement in operating cash generation, with net cash generated from operating activities reaching Rs. 1.65 billion, compared with Rs. 100 million in the same period last year.
The strong quarterly performance highlights GSK Pakistan’s continued ability to expand revenue and improve profitability while maintaining a healthy balance sheet and solid cash flows, positioning the pharmaceutical company for sustained operational growth in 2026.
